Investigating the Acute Effects of Increasing Glucagon Exposure in Healthy Participants

Exclusion Criteria

• •Enrolment in other research projects that might interfere with the study
• •Diabetes diagnosis (type 1 and 2)
• •Pregnancy or breastfeeding
• •Use of medications which, in the opinion of the investigator, may jeopardise participant's safety or compliance with the protocol
• •Impaired liver function defined as either alanine aminotransferase (ALAT) and/or aspartate aminotransferase (ASAT) ≥ 2 times normal values
• •Kidney disease defined as serum creatinine levels ≥ 126 μmol/L for male and ≥ 111 μmol/L for female
• •Inadequately treated blood pressure at screening defined as repeated resting blood pressure outside the range 90-150 mmHg for systolic and 50-100 mmHg for diastolic
• •Active or recent malignant disease
• •Current or history of severe alcohol use or drug/chemical abuse as per investigator's judgement
• •Any chronic disorders or severe diseases which, in the opinion of the investigator, might jeopardise participant's safety or compliance with the protocol